Entering text into the input field will update the search result below

Sage Therapeutics: Biogen's Backing May See It Through

Jan. 03, 2022 7:49 PM ETSage Therapeutics, Inc. (SAGE)4 Comments


  • Sage's zuranolone has failed to be tremendously impressive in clinical trials.
  • However, Sage is backed by Biogen, a company with a magician's regulatory prowess.
  • So that makes zuranolone's regulatory chances stronger, even if commercial success is less certain.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Loneliness Teenage Girls

xijian/E+ via Getty Images

Since I covered Sage Therapeutics (NASDAQ:SAGE) in February, the stock is down 50% - another sad reminder of how bad 2021 has been for the entire biopharma sector. In my previous article, I noted how SAGE recovered from the

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (4)

Sage has a lot of cash on hand. How long a cash runway is this? Enough to finish up their products?
Stan Piland profile picture
Good article thanks. Sounds like I should give SAGE closer attention. I'm curious, have you looked at Vistagen (VTGN) in this space? I consider it a potential undiscovered gem in the treatment of Depression/Social Anxiety Disorder. Their lead product is PH94B, a pherine nasal spray for episodic treatment of SAD. Since it's non-systemic, early results show a remarkably benign safety profile. Initial P3 results are due mid-year, and they already have fast-track designation from the FDA. Earlier stage products include PH10, another pherine nasal spray for Major Depressive Disorder. Give it a look, and thanks again!
One of the most easily understandable pieces covering a biopharma, and touching on the past, present, and future scenarios quite nicely.
Avisol Capital Partners profile picture
@spinlessandfactful Thanks for reading, and for the kind comment. Always available to respond to questions.

Dr Ashok Dutta
The Total Pharma Tracker
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.